Evidence to date: talazoparib in the treatment of breast cancer
Authors:
Open Access
- 1 July 2019
- journal article
- review article
- Published by Taylor & Francis in OncoTargets and Therapy
- Vol. ume 12, 5177-5187
Abstract
Approximately 5–10% of all patients diagnosed with breast cancer have germline BRCA1/2 mutations, which make their disease more susceptible to DNA-damaging agents and a new class of drugs known as poly(ADP-ribose) polymerase (PARP) inhibitors. Talazoparib is a new PARP inhibitor that has been recently approved for use in patients with metastatic breast cancer with germline BRCA mutations after a phase III trial showed superior progression-free survival when compared to standard chemotherapy. In this review, we analyze the development of talazoparib as well as its safety profile and the potential role of the combination therapy with standard cytotoxic drugs and with novel therapies.Keywords
This publication has 34 references indexed in Scilit:
- Unsolved mystery: the role of BRCA1 in DNA end-joiningJournal of Radiation Research, 2016
- STING: infection, inflammation and cancerNature Reviews Immunology, 2015
- Stereospecific PARP Trapping by BMN 673 and Comparison with Olaparib and RucaparibMolecular Cancer Therapeutics, 2014
- BMN 673, a Novel and Highly Potent PARP1/2 Inhibitor for the Treatment of Human Cancers with DNA Repair DeficiencyClinical Cancer Research, 2013
- Trapping of PARP1 and PARP2 by Clinical PARP InhibitorsCancer Research, 2012
- Olaparib Maintenance Therapy in Platinum-Sensitive Relapsed Ovarian CancerNew England Journal of Medicine, 2012
- Breast and cervical cancer in 187 countries between 1980 and 2010: a systematic analysisThe Lancet, 2011
- Cancer-predisposing mutations within the RING domain of BRCA1: Loss of ubiquitin protein ligase activity and protection from radiation hypersensitivityProceedings of the National Academy of Sciences, 2001
- BRCA1 Is Associated with a Human SWI/SNF-Related ComplexCell, 2000
- PARP-2, A Novel Mammalian DNA Damage-dependent Poly(ADP-ribose) PolymeraseJournal of Biological Chemistry, 1999